Table 1.
Baseline characteristics
| Cisplatin and fluorouracil (n=451) | Epirubicin, cisplatin, and capecitabine (n=446) | |
|---|---|---|
| Sex | ||
| Female | 39 (9%) | 48 (11%) |
| Male | 412 (91%) | 398 (89%) |
| Age, years | ||
| Median (IQR) | 62 (57–67) | 62 (56–67) |
| Range | 27–81 | 33–80 |
| WHO performance status | ||
| 0 | 311 (69%) | 292 (65%) |
| 1 | 140 (31%) | 154 (35%) |
| Stage of tumour* | ||
| T1 N1 | 3 (1%) | 5 (1%) |
| T2 N1 | 49 (11%) | 41 (9%) |
| T3 N0 | 97 (22%) | 99 (22%) |
| T3 N1 | 287 (64%) | 289 (65%) |
| T4 N0† | 3 (1%) | 1 (<1%) |
| T4 N1† | 12 (3%) | 11 (2%) |
| Participating in quality-of-life assessment | ||
| Yes | 435 (96%) | 424 (95%) |
| No | 16 (4%) | 22 (5%) |
Data are n (%) unless otherwise specified.
*
Stage of tumour (based on both endoscopic ultrasonography and CT results) was used to stratify randomisation.
†
Specific site of T4 invasion is mediastinal pleura for eight patients (four in the cisplatin and fluorouracil group vs four in the epirubicin, cisplatin, and capecitabine group), crura for 14 patients (nine vs five), and diaphragm for five patients (two vs three).